Trial record 1 of 1 for:
NCT04115293
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04115293 |
Recruitment Status :
Completed
First Posted : October 4, 2019
Results First Posted : January 17, 2023
Last Update Posted : May 2, 2024
|
Sponsor:
Ra Pharmaceuticals, Inc.
Information provided by (Responsible Party):
UCB Pharma ( Ra Pharmaceuticals, Inc. )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Myasthenia Gravis, Generalized |
Interventions |
Drug: zilucoplan (RA101495) Drug: Placebo |
Enrollment | 174 |
Participant Flow
Recruitment Details | The study started to enroll participants in September 2019 and concluded in December 2021. |
Pre-assignment Details | The Participant flow refers to the Randomized Set. |
Arm/Group Title | Placebo | Zilucoplan 0.3 mg/kg |
---|---|---|
Arm/Group Description | Participants self-administered zilucoplan (RA101495) matching placebo as subcutaneous (SC) injection during 12-week Treatment Period. | Participants self-administered zilucoplan (RA101495) 0.3 milligrams/kilogram/day (mg/kg/day) SC injection during 12-week Treatment Period. |
Period Title: Overall Study | ||
Started | 88 | 86 |
Completed | 84 | 82 |
Not Completed | 4 | 4 |
Reason Not Completed | ||
Adverse Event | 0 | 2 |
Withdrawal by Subject | 2 | 1 |
Physician Decision | 1 | 0 |
Death | 1 | 1 |
Baseline Characteristics
Arm/Group Title | Placebo | Zilucoplan 0.3 mg/kg | Total | |
---|---|---|---|---|
Arm/Group Description | Participants self-administered zilucoplan (RA101495) matching placebo as subcutaneous (SC) injection during 12-week Treatment Period. | Participants self-administered zilucoplan (RA101495) 0.3 milligrams/kilogram/day (mg/kg/day) SC injection during 12-week Treatment Period. | Total of all reporting groups | |
Overall Number of Baseline Participants | 88 | 86 | 174 | |
Baseline Analysis Population Description |
The modified Intention-to-Treat (mITT) population included all randomized participants who received at least 1 dose of study drug and had at least 1 post-dosing MG-ADL score.
|
|||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 88 participants | 86 participants | 174 participants | |
<=18 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Between 18 and 65 years |
62 70.5%
|
64 74.4%
|
126 72.4%
|
|
>=65 years |
26 29.5%
|
22 25.6%
|
48 27.6%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 88 participants | 86 participants | 174 participants | |
53.3 (15.7) | 52.6 (14.6) | 53.0 (15.1) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 88 participants | 86 participants | 174 participants | |
Female |
47 53.4%
|
52 60.5%
|
99 56.9%
|
|
Male |
41 46.6%
|
34 39.5%
|
75 43.1%
|
|
Race/Ethnicity, Customized
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 88 participants | 86 participants | 174 participants |
American Indian/Alaska native |
1 1.1%
|
0 0.0%
|
1 0.6%
|
|
Asian |
14 15.9%
|
7 8.1%
|
21 12.1%
|
|
Black |
7 8.0%
|
6 7.0%
|
13 7.5%
|
|
Native Hawaiian or other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
White |
62 70.5%
|
66 76.7%
|
128 73.6%
|
|
Other/Mixed |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Missing |
4 4.5%
|
7 8.1%
|
11 6.3%
|
|
Race/Ethnicity, Customized
Measure Type: Count of Participants Unit of measure: Participants |
Number Analyzed | 88 participants | 86 participants | 174 participants |
Hispanic or Latino |
5 5.7%
|
7 8.1%
|
12 6.9%
|
|
Not Hispanic or Latino |
79 89.8%
|
72 83.7%
|
151 86.8%
|
|
Missing |
4 4.5%
|
7 8.1%
|
11 6.3%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | UCB |
Organization: | Cares |
Phone: | 001 844 599 2273 |
EMail: | UCBCares@ucb.com |
Publications of Results:
Responsible Party: | UCB Pharma ( Ra Pharmaceuticals, Inc. ) |
ClinicalTrials.gov Identifier: | NCT04115293 |
Other Study ID Numbers: |
RA101495-02.301 |
First Submitted: | October 2, 2019 |
First Posted: | October 4, 2019 |
Results First Submitted: | December 19, 2022 |
Results First Posted: | January 17, 2023 |
Last Update Posted: | May 2, 2024 |